Trovagene Expands Collaboration with Genomac to Demonstrate Clinical Utility in Lung and Colorectal Cancer Treatment Monitoring
Prospective clinical studies to evaluate Trovagene’s Precision Cancer Monitoring platform to determine the emergence of resistance mutations using circulating tumor DNA
SAN DIEGO – January 21, 2015 – Trovagene, Inc. (NASDAQ: TROV), today announced it will expand the clinical collaboration with Genomac Research Institute in Prague, Czech Republic. Trovagene Precision Cancer Monitoring SM technology will be used in two prospective clinical studies for the early detection of emerging oncogene mutations indicative of resistance to targeted therapies used to treat colorectal and lung cancer.
Comparable test results were shown with both urine and plasma molecular assays in a blinded, retrospective study that evaluated the potential of quantitating KRAS circulating tumor (ct)DNA in patients with minimal residual disease (MRD) surgical colorectal cancer (CRC) who have liver metastases.
A correct KRAS mutation was identified in 95% of archival plasma specimens by the assay and in 92% of archival urine specimens from patients with CRC and known KRAS mutational status in tumor tissue, according to data presented at the 2015 Gastrointestinal Cancers Symposium by Marek Minarik, PhD, director at Genomac International and assistant professor at Charles University, Prague, Czech Republic.1